Preparation and Immune Effect of HEV ORF2 P206@PLGA Nanoparticles.

ABSTRACT: The hepatitis E virus (HEV) is an important pathogen that threatens global public health. One-third of the world's population lives in the epidemic area of HEV, causing 20 million infections and 70,000 deaths annually. In China, HEV transmission has changed from human-to-human transmission of HEV1 to zoonotic transmission of HEV4, causing hepatitis outbreaks throughout the country. Protecting vulnerable groups, such as practitioners related to animal husbandry and downstream consumers who are immune deficient or pregnant, from HEV infections is an urgent task. At present, the commercial human vaccine, Hecolin^® (HEV 239 vaccine), is licensed for use only in China. HEV 239 vaccine is a human vaccine developed for HEV1. Although it has a cross-protective effect on HEV4, the level o

SUBMITTER: Yang Y 

PROVIDER: S-EPMC8878542 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature